Leena Das-Young,Keith David Wilner,Steffan Nicholas Ho
申请号：
US15506316
公开号：
US20170274074A1
申请日:
2015.08.24
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.
